Virginia Tech
Improving Potency and Oral Bioavailability of Spinster Homolog 2 (Spns2) Inhibitor: A Structure-Activity Relationship Study
Abstract
dc:description.abstractThe sphingosine-1-phosphate (S1P) pathway is a therapeutic target for drug discovery due to its involvement in autoimmune diseases such as multiple sclerosis (MS) and ulcerative colitis (UC) as well as renal fibrosis (RF). S1P is synthesized from sphingosine that is phosphorylated by sphingosine kinases 1 or 2 (SphK1, SphK2). Once formed, it can be transported to extracellular space by one of its transporter proteins spinster homolog 2 (Spns2) or major facilitator superfamily domain containing 2b (MFSd2b) to interact with its five G-protein coupled receptors S1P1-5. Once receptor bound, S1P can elicit a variety of signaling responses involving cellular survival, migration, and proliferation. Of note, S1P-S1P1 interactions induce the egress of lymphocytes from lymph. As a result, the S1P pathway has been the focus of several successful medicinal chemistry campaigns with five S1P receptor modulators receiving FDA approval for the treatment of MS and/or UC. However, these S1P receptor modulators suffer from adverse on-target cardiovascular side effects. To circumvent these side effects, targeting proteins upstream of the receptors has become the focus from medicinal chemistry campaigns. In this dissertation, the design and development of Spns2 inhibitors is reported. A complete structure-activity relationship (SAR) studies of the head, core, and tail region of the Spns2 inhibitors pharmacophore was performed, resulting in several inhibitors with improved potency, oral bioavailability, and pharmacokinetic properties. From this SAR we discovered that: (i) a urea piperazine head group improves potency and oral bioavailability, (ii) additional substitution on the phenyl core was detrimental to inhibitor activity, and (iii) replacement of the lipid-like decyl tail with less lipophilic and more rigid tails were well tolerated, preventing the inhibitor from rapid metabolism while maintaining potency and oral bioavailability. The optimized Spns2 inhibitor, 4.22v, contains a urea-piperazine head group, a phenyl core, and a 3-cyclopropylphenol-butylene tail. In vitro studies revealed that 4.22v impaired S1P transport on par with the transport dead mutant Spns2R200S when administered at 300 nM and an IC50 of 23 ± 1 nM. Intraperitoneal injection (IP) and oral gavage (PO) administration of 4.22v to mice resulted in profound lymphopenia, a hallmark of in vivo Spns2 inhibition. Preliminary pharmacokinetic studies determined that 4.22v has a half-life of 6.9 hours in mice and chronic dosing at 20 mg/kg for 14 days did not show signs of toxicity. With these results, 4.22v is a potential drug candidate for the treatment of MS, UC, or RF and is currently undergoing further biological evaluation.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Chemistry
- Department dc:contributor.department
- Chemistry
- Grantor dc:publisher
- Virginia Tech
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Dunnavant, Kyle Jacob
- Chair dc:contributor.committeechair
-
- Santos, Webster
- Committee members dc:contributor.committeemember
-
- Mevers, Emily
- Tanko, James M.
- Lowell, Andrew Nesemann
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- In Copyright
- Licence dc:rights.uri
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Dc Identifier Other
- vt_gsexam:40143